Helus Pharma Inc. HELP
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Helus Pharma Inc. (HELP) is a healthcare company listed in the US with a market value of about $648M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
About Helus Pharma
Helus Pharma is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 5 years in our data.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $685334 |
| Net income | -$79M | -$58M | -$35M | -$54M | -$26M |
| Free cash flow | — | -$51M | -$35M | -$36M | -$15M |
| EPS (diluted) | $-1.08 | $-0.79 | $-0.48 | $-0.74 | $-0.35 |
| Net margin | — | — | — | — | -3729.2% |
| ROIC | — | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $40.61, 358% above the current price; targets range from $14.85 to $68.93; the consensus rating is “Strong buy”; expected EPS is $-4.10 for the fiscal year ending March 31, 2027.
Frequently asked questions
Does Helus Pharma pay a dividend?
Not currently.
Is Helus Pharma a good stock to buy?
We do not give buy or sell advice. Helus Pharma scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.